Early Secreted Antigenic Target 6 kDa (ESAT-6), encoded by the esxA gene within the RD1 region of Mycobacterium tuberculosis, is a small, secreted protein that sits at the heart of mycobacterial virulence. Working in tight partnership with its chaperone CFP-10, ESAT-6 is exported by the ESX-1 type VII secretion system and acts on host membranes and immune signaling pathways to enable intracellular survival of the bacillus. This review focuses on the molecular architecture of ESAT-6, its secretion mechanism, its pH-dependent interactions with phagosomal membranes, and its downstream effects on host cell death pathways and immune signaling. To support infectious disease and immunology research, we provide flexible and reliable analysis services using protein array technology, meeting diverse needs in cytokine profiling, antigen reactivity assays, and host-pathogen interaction biomarker discovery.
Introduction
ESAT-6 (Early Secreted Antigenic Target 6 kDa) is a small, highly immunogenic secreted protein that has emerged as one of the most intensively studied virulence factors of Mycobacterium tuberculosis. The protein is encoded by the esxA gene, which is located within the region of difference 1 (RD1) of the M. tuberculosis genome—a 9.5-kb segment that is absent from the BCG vaccine strain and from most non-tuberculous mycobacteria. The very absence of ESAT-6 from BCG has historically been linked to the attenuation of this vaccine, and the subsequent reintroduction of ESX-1 components into recombinant BCG strains restores significant virulence, providing one of the earliest causal links between ESAT-6 secretion and M. tuberculosis pathogenicity.
At the molecular level, ESAT-6 does not act alone. It is co-transcribed with its chaperone, CFP-10 (Culture Filtrate Protein 10, encoded by esxB), and the two proteins form an unusually tight 1:1 heterodimer that remains associated throughout most of the secretion process. Once outside the bacterial cell, however, ESAT-6 is increasingly recognized as the active effector, with CFP-10 serving as a molecular chaperone and secretion-tagging partner. This functional asymmetry between two small proteins of similar size is the central molecular puzzle of the ESAT-6/CFP-10 system, and the resolution of this puzzle has shaped much of the current understanding of M. tuberculosis virulence.
The biological activities of ESAT-6 span an unusually broad spectrum for a small secreted protein. ESAT-6 contributes to phagosomal membrane damage, allowing M. tuberculosis to access the host cytosol; it modulates host cell death pathways, including apoptosis, pyroptosis, and necroptosis; it shapes innate immune signaling through pattern recognition receptors, NF-κB activation, and inflammasome assembly; and it serves as a major target of adaptive T cell immunity.
Molecular Architecture of ESAT-6 and the ESAT-6/CFP-10 Heterodimer
ESAT-6 is a 95-residue protein with a molecular mass of approximately 10 kDa (the apparent 6 kDa on SDS-PAGE reflects its anomalous migration). Despite its small size, the protein adopts a well-defined tertiary structure composed of two long α-helices that pack against each other in an antiparallel arrangement, with a short connecting loop. The structure of ESAT-6 was first characterized in complex with CFP-10, which revealed a tight 1:1 heterodimer in which the two proteins each contribute one long α-helix to a four-helix bundle. In this complex, the ESAT-6 and CFP-10 helices are intertwined along their entire length, forming an elongated, rod-like structure of approximately 60 Å in length.
The ESAT-6/CFP-10 interaction is among the tightest known protein-protein interactions in mycobacterial biology, with a dissociation constant in the low-nanomolar range. The structural basis for this high affinity is the extensive burial of hydrophobic surface area along the four-helix interface, combined with a network of polar and electrostatic contacts at the helix termini. The C-terminal residues of ESAT-6 extend beyond the core four-helix bundle and project as a flexible tail that, in the complex, remains partially solvent-exposed.
Functional studies have revealed that this C-terminal tail is critical for ESAT-6's membrane-damaging activity. Site-directed mutagenesis of the C-terminal residues of ESAT-6 abolishes its ability to damage phagosomal membranes and to support M. tuberculosis virulence in macrophages and in animal models, even when secretion of the mutant protein is preserved at near-wild-type levels. This finding established that the C-terminal tail of ESAT-6 is a major functional determinant, and that the membrane-damaging activity of ESAT-6 is not merely a passive consequence of its secretion but is a discrete, structurally encoded activity.
Figure 1. Control of ESAT-6 secretion by PhoP-dependent regulatory networks. (Source: Anes E, et al. 2023)
The ESX-1 Type VII Secretion System
ESAT-6 is exported from the mycobacterial cytoplasm by the ESX-1 system, a type VII secretion system (T7SS) encoded within the RD1 region. ESX-1 is the founding member of the mycobacterial type VII secretion family, which comprises five paralogous systems (ESX-1 through ESX-5) in M. tuberculosis. ESX-1 is the most thoroughly characterized of these and is the only one that has been shown unambiguously to be required for full virulence. The ESX-1 apparatus is a multi-subunit, envelope-spanning complex that uses the proton motive force to drive the translocation of folded protein substrates across the unusual diderm cell envelope of mycobacteria.
The substrates of ESX-1 include the ESAT-6/CFP-10 heterodimer as well as a number of additional proteins that are secreted in an ESX-1-dependent manner, some of which may also contribute to virulence. Among these are EspA, EspC, and EspD, which form a separate secretion pathway that intersects with ESX-1 and is required for ESAT-6 secretion in some contexts. The substrate specificity of ESX-1 is determined in part by a C-terminal secretion signal that is shared among ESX-1 substrates, and the recognition of this signal by the ESX-1 apparatus is one of the central mechanistic questions in the T7SS field.
The importance of ESX-1 in M. tuberculosis virulence is supported by extensive genetic evidence. Deletion of the ESX-1 locus results in severe attenuation in macrophages and in animal infection models, and the loss of ESAT-6 secretion alone is sufficient to phenocopy much of this attenuation. Conversely, heterologous expression of ESX-1 in non-pathogenic mycobacteria, or in BCG, is sufficient to confer many of the virulence-associated phenotypes observed in M. tuberculosis, including the ability to damage phagosomal membranes and to induce host cell death. The ESX-1 system has therefore emerged as a central target for the development of both new anti-tuberculosis drugs and improved live attenuated vaccines.
Phagosomal Membrane Damage and the pH-Dependent Activity of ESAT-6
The most distinctive and best-characterized functional activity of ESAT-6 is its ability to damage the phagosomal membrane that surrounds internalized M. tuberculosis within host macrophages. This membrane-damage activity is the molecular basis for the so-called "phagosomal rupture" phenomenon, in which M. tuberculosis escapes from the phagosomal compartment into the host cytosol, where it can access cytosolic nutrients and evade phagosome-dependent host defense mechanisms.
The membrane-damaging activity of ESAT-6 is pH-dependent. At neutral pH, ESAT-6 forms a tight heterodimer with CFP-10 that is largely soluble and shows little affinity for lipid membranes. Upon acidification to the pH characteristic of the phagosome-to-phagolysosome transition (approximately pH 5.5–6.0), however, ESAT-6 undergoes a conformational rearrangement that releases it from CFP-10, exposes hydrophobic residues on its surface, and drives self-association into higher-order oligomers. These oligomers are capable of binding to and disrupting lipid bilayers, leading to membrane destabilization and rupture. Recent single-molecule and real-time imaging studies have directly visualized the ESAT-6-mediated rupture of phagosomal membranes in living macrophages, providing some of the most compelling evidence to date for the central role of ESAT-6 in this process.
At the membrane level, ESAT-6 has been shown to interact preferentially with membranes containing specific lipid components, including phosphatidylinositol and cardiolipin. This lipid preference may help explain why ESAT-6 disrupts phagosomal membranes but leaves the plasma membrane of the host cell largely intact, at least during the early stages of infection. The C-terminal tail of ESAT-6 plays a central role in this membrane interaction, and its deletion or mutation abolishes both membrane binding and membrane damage in model systems.
The biological consequences of phagosomal rupture are extensive. By accessing the cytosol, M. tuberculosis gains access to cytosolic nutrients and evades the maturation arrest that the phagosome normally imposes. In addition, cytosolic exposure of mycobacterial DNA, RNA, and other PAMPs activates cytosolic immune sensors, including the cGAS-STING pathway and the NLRP3 inflammasome, leading to a distinctive type I interferon and inflammasome-driven host response that differs from the response to phagosome-contained bacilli.
Figure 2. Effects of ESAT-6 on the outcome of Mtb infection in host macrophages. (Source: Anes E, et al. 2023)
ESAT-6 and Host Cell Death Pathways
The disruption of phagosomal membranes by ESAT-6 has profound consequences for the host cell death program. M. tuberculosis-infected macrophages exhibit a complex spectrum of cell death outcomes, including apoptosis, pyroptosis, and necroptosis, and ESAT-6 has been implicated in the regulation of each of these.
Apoptosis is generally considered an anti-mycobacterial outcome, because apoptotic cells are efficiently cleared by phagocytes and limit the spread of infection. ESAT-6 has been shown to modulate apoptosis through multiple mechanisms, including the regulation of mitochondrial membrane potential, the modulation of Bcl-2 family members, and the activation of caspase-dependent and caspase-independent pathways. Whether ESAT-6 promotes or inhibits apoptosis appears to depend on the experimental system, the dose and timing of ESAT-6 exposure, and the cell type examined. In some settings, ESAT-6 promotes apoptosis and thereby limits bacterial survival, while in others it inhibits apoptosis and supports intracellular persistence.
Pyroptosis, an inflammasome-driven form of cell death that releases pro-inflammatory cytokines such as IL-1β and IL-18, is a major response to cytosolic M. tuberculosis. ESAT-6 is one of the principal mycobacterial activators of the NLRP3 inflammasome, acting through its membrane-damaging activity to trigger potassium efflux and other canonical inflammasome-activating signals. Recent studies have shown that ESAT-6-mediated membrane damage drives caspase-1 activation, gasdermin D cleavage, and the release of IL-1β from infected macrophages, establishing a clear mechanistic link between ESAT-6 secretion, phagosomal rupture, and inflammasome activation. The cGAS-STING pathway is also activated downstream of ESAT-6-mediated membrane damage, leading to the induction of type I interferons and the modulation of the broader host response to infection.
Necroptosis, a programmed form of inflammatory cell death, has also been implicated in the response to M. tuberculosis, and ESAT-6 has been reported to sensitize infected macrophages to necroptotic death through the engagement of the RIPK1-RIPK3-MLKL axis. Together, these findings position ESAT-6 as a central regulator of the host cell death landscape, with effects that vary depending on the local concentration of ESAT-6, the cell type, and the broader immune environment.
Modulation of Host Immune Signaling
Beyond its effects on cell death, ESAT-6 modulates a wide range of host signaling pathways that shape the innate and adaptive immune response to M. tuberculosis. At the level of pattern recognition, ESAT-6 has been reported to interact with TLR2 and TLR4 on the surface of macrophages and dendritic cells, leading to the activation of MyD88-dependent signaling and the production of pro-inflammatory cytokines. ESAT-6 has also been shown to influence the activity of antigen-presenting cells, including the maturation and migration of dendritic cells, and to modulate the production of chemokines that recruit monocytes and neutrophils to the site of infection.
ESAT-6 also influences adaptive immunity. As one of the most immunogenic M. tuberculosis antigens, ESAT-6 is a major target of CD4+ and CD8+ T cell responses, and the ESAT-6-specific T cell response is a key component of the protective immune response to M. tuberculosis. However, ESAT-6 can also suppress the activity of T cells through direct effects on T cell signaling, including the inhibition of IFN-γ production through the downregulation of the transcription factors ATF-2 and c-Jun. This dual role—as both a T cell target and a T cell modulator—adds a layer of complexity to the immunological role of ESAT-6 and may contribute to the chronic nature of M. tuberculosis infection.
At the systems level, ESAT-6 sits at the intersection of multiple signaling networks that collectively determine the outcome of infection. The same protein that activates inflammasomes and induces pyroptosis also suppresses T cell activity, modulates chemokine production, and damages phagosomal membranes. Integrating these diverse activities into a coherent picture of ESAT-6 function is one of the central challenges of current tuberculosis research, and a complete understanding will require both molecular dissection of individual ESAT-6 interactions and systems-level analysis of host signaling networks in infected cells.
Frequently Asked Questions (FAQs)
ESX-1 is a type VII secretion system (T7SS) encoded within the RD1 region of the M. tuberculosis genome. It is a multi-subunit, envelope-spanning complex that exports ESAT-6, CFP-10, and several other protein substrates across the unusual diderm cell envelope of mycobacteria. ESX-1 is essential for full M. tuberculosis virulence, and deletion of the ESX-1 locus results in severe attenuation in macrophages and in animal models.
Yes. Protein array platforms enable the parallel, quantitative measurement of dozens of host signaling markers—including cytokines, chemokines, inflammasome readouts, and signaling phosphoproteins—from a single small-volume sample. Combined with M. tuberculosis antigen reactivity assays (including ESAT-6-specific IgG and T cell cytokine responses), these platforms can provide a multidimensional picture of the host-pathogen interface in TB and in host-pathogen interaction studies more broadly.
Key challenges include the difficulty of purifying sufficient amounts of active ESAT-6 for biochemical studies; the limited resolution of current structural models of the ESX-1 apparatus; the complex and context-dependent effects of ESAT-6 on host signaling pathways; and the limited integration of molecular, cellular, and systems-level data into a coherent picture of ESAT-6 function. Multi-omics approaches that combine transcriptomics, proteomics, and functional arrays are actively being developed to address these limitations.
References
- Anes E, et al. ESAT-6 a Major Virulence Factor of Mycobacterium tuberculosis. Biomolecules. 2023 Jun 9;13(6):968.
- Pym AS, et al. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. Nat Med. 2003 May;9(5):533-9.
- Renshaw PS, et al. Structure and function of the complex formed by the tuberculosis virulence factors CFP-10 and ESAT-6. EMBO J. 2005 Jul 20;24(14):2491-8.
- Gröschel MI, et al. ESX secretion systems: mycobacterial evolution to counter host immunity. Nat Rev Microbiol. 2016 Nov;14(11):677-691.
- Bates TA, et al. ESAT-6 undergoes self-association at phagosomal pH and an ESAT-6-specific nanobody restricts M. tuberculosis growth in macrophages. Elife. 2024 May 28;12:RP91930.
- Beckwith KS, et al. Plasma membrane damage causes NLRP3 activation and pyroptosis during Mycobacterium tuberculosis infection. Nat Commun. 2020 May 8;11(1):2270.
- Kunnath-Velayudhan S, Davidow AL, Wang HY, Molina DM, Huynh VT, Salamon H, Pine R, Michel G, et al. Proteome-scale antibody responses and outcome of Mycobacterium tuberculosis infection in nonhuman primates and in tuberculosis patients. J Infect Dis. 2012 Sep 1;206(5):697-705.